Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer: an Open-label, Multicenter, Single Arm Phase 2 Study

NCT06055465 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT06055465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06055465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer: an Open-label, Multicenter, Single Arm Phase 2 Study
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 28, 2024
Completion date
December 30, 2029
Enrollment
37 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer